Sutimlimab Biosimilar - Research Grade

Specifications

Catalog number

ICH5012-5mg

Size / count

5 mg

Dry ice

No

Hazardous

No

Discontinued

No

Background

RUO sutimlimab biosimilar is a humanized monoclonal antibody that is designed to selectively target and inhibit C1s in the classical complement pathway, which is part of the innate immune system. By blocking C1s, sutimlimab inhibits the activation of the classical complement pathway with the goal of halting C1-activated hemolysis in cold agglutinin disease to prevent the abnormal destruction of healthy red blood cells. By selectively inhibiting the classical pathway upstream at C1s, sutimlimab does not inhibit the lectin and alternative complement pathways.

Specifications

Detects human C1s. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Sutimlimab.

UniProt

P09871

Species Reactivity

Human

Target

C1s

Isotype

IgG4

Applications

Functional Assays

Purification Method

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Concentration

5mg/mL

Endotoxin

≤ 1.0 EU/mg as determined by the LAL method

Purity

>95% by SDS-PAGE

Buffer

ICH3002

Shipping Conditions

Blue ice

Storage Conditions

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Formulation

Sterile, preservative-free, solution in PBS. BSA and Azide free.

Applications Notes

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Isotype Control

https://ichor.bio/product/bulk-human-igg4-isotype-control-ib4-ich2257/